Skip to main content
. 2019 Nov 13;45(1):81–92. doi: 10.3892/ijmm.2019.4406

Figure 1.

Figure 1

CBX attenuates MCT-induced pulmonary hypertension and right ventricular hypertrophy in an MCT-induced rat model of pulmonary inflammation. (A) Representative pulse-wave Doppler acquisition of pulmonary flow in the control, CBX + single intraperitoneal injection of CBX, MCT and MCT + CBX groups. The distance between the 2 red dashed line in each group represents PAAT. (B) PAAT from onset of pulmonary valve flow to peak velocity as a surrogate measure of mean pulmonary arterial pressure measured by pulsed wave-Doppler echocardiography. PAAT is negatively correlated to mean pulmonary arterial pressure and pulmonary vascular resistance measured. Statistical analysis of PAAT in the four experimental groups. PAAT was significantly decreased in the MCT treatment group compared with the control group after 28 days. Treatment with CBX significantly increased PAAT compared with the MCT group. (C) CBX administration decreased RVHI (the ratio of RV weight/left ventricular plus septal weight) in MCT-treated rats. Data are presented as the mean ± standard error of the mean of 6 rats per group. **P<0.01 vs. Control and CBX group treated with a single intraperitoneal injection of CBX. #P<0.05 vs. MCT + CBX group. CBX, carbenoxolone; MCT, monocrotaline; CON, control; PAAT, pulmonary artery valve flow acceleration time; RVHI, right ventricle hypertrophy index.